1. Market Research
  2. > Healthcare
  3. > Diagnostics Market Trends
  4. > Next-Generation Cancer Diagnostics Market Forecast 2015-2025: Opportunities for Leading Companies Developing Advanced PCR Techniques, CTC tests, FISH tests, Microarrays and NGS Technologies

Report Details
Next-generation cancer diagnostics – our new study reveals trends, R&D progress, and predicted revenues
Where is the next-generation cancer diagnostics market heading? If you are involved in this sector you must read this brand new report. Visiongain’s report shows you the potential revenues streams to 2025, assessing data, trends, opportunities and business prospects there.

Discover How to Stay Ahead
Our 176-page report provides 87 tables, charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market, submarket and regional level. You will see financial results, interviews, trends, opportunities, and revenue predictions. Much opportunity remains in the growing next-generation cancer diagnostics market.

Forecasts from 2015-2025 and other analyses reveal the commercial prospects
- In addition to revenue forecasting to 2025, our new study provides you with recent results, growth rates, and market shares.
- You will find original analyses, with business outlooks and developments.
- Discover qualitative analyses (including SWOT analysis), product profiles and commercial developments.
- Read the full transcripts of two exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales, including:
- Keith Cannon, Executive Vice President, Aviva Biosciences
- Nobuyoshi Katagiri, Ph.D., Director, Diagnostics Development Department, Oncolys BioPharma

Discover sales predictions for the world market and submarkets
Along with revenue prediction for the overall world market, you will find revenue forecasts to 2025 for the following submarkets:
- Advanced PCR Techniques
- In Situ Hybridisation
- Circulating Tumour Cells
- Microarray
- Next-Generation Sequencing

Our investigation discusses what stimulates and restrains business. You will understand the dynamics of the industry and assess its potential future sales, discovering the critical factors likely to achieve success.

Our analysis also divides the main global forecast into geographical markets.

What are the prospects in the leading regions and countries?
You will discover individual revenue forecasts for leading national markets from 2015-2025:
- US
- Japan
- EU5 (Germany, France, UK, Italy and Spain) as a group
- China
- India
- Brazil
- Russia
- Rest of the World

There will be growth in established developed markets and in developing countries. Our analyses show that China, in particular, will continue to achieve high revenue growth to 2025. Greater uptake of existing technology and products worldwide will also stimulate the industry and market.

Leading companies and the potential for market growth
Overall world revenue for next-generation cancer diagnostics will reach $1.6bn in 2015, our work calculates. We predict strong revenue growth through to 2025. Market entry of NGS and CTCs together with increasing demand from emerging markets will increase sales to 2025.

Our work identifies which organisations that hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead. See visiongain’s analysis of the leading companies developing the most innovative cancer diagnostic technologies, including these:

- Roche Diagnostics
- Abbott Laboratories
- Qiagen
- Thermo Fisher Scientific
- Agilent Technologies
- Hologic
- Illumina
- Myriad Genetics

What issues will affect the next-generation cancer diagnostics industry?
Our new report discusses the issues and events affecting the next-generation cancer diagnostics market. You will find discussions, including qualitative analyses:

- Savings

Table Of Contents

Next-Generation Cancer Diagnostics Market Forecast 2015-2025: Opportunities for Leading Companies Developing Advanced PCR Techniques, CTC tests, FISH tests, Microarrays and NGS Technologies
Table of Contents
1. Executive Summary
1.1 Overview of Findings
1.2 Structure of the Report
1.3 Global Next-Generation Cancer Diagnostics Market Segmentation
1.4 Why You Should Read This Report
1.5 How This Report Delivers
1.6 Key Questions Answered by This Analytical Report
1.7 Who is This Report For?
1.8 Methodology
1.9 Frequently Asked Questions (FAQ)
1.10 Associated Visiongain Reports
1.11 About Visiongain

2. Introduction to Next-Generation Cancer Diagnostics
2.1 What Is Cancer?
2.2 Cancer Diagnostics: An Overview
2.2.1 Screening
2.2.2 Diagnosis
2.2.3 Staging
2.3 Cancer Diagnosis Methods
2.3.1 Physical Examination
2.3.2 Imaging Techniques
2.3.2.1 Ultrasound
2.3.2.2 Computed Tomography (CT)
2.3.2.3 Magnetic Resonance Imaging (MRI)
2.3.2.4 Positron Emission Tomography (PET)
2.3.3 Histopathological and Cytological Techniques
2.3.4 Immunohistochemistry (IHC) Analysis
2.3.5 Circulating Tumour Cell (CTC) Analysis
2.3.6 Molecular Diagnostics and IVD
2.3.6.1 Polymerase Chain Reaction (PCR)
2.3.6.2 Multiplex PCR
2.3.6.3 Real-Time PCR (RT-PCR or qPCR)
2.3.6.4 Digital PCR (dPCR)
2.3.6.5 In Situ Hybridisation (ISH)
2.3.6.6 Microarray
2.3.6.7 Next-Generation Sequencing (NGS)
2.4 Tests for Inherited and Acquired Genetic Mutations
2.5 Companion Diagnostics (CDx)
2.6 Laboratory Developed Test (LDT)
2.7 Precision Medicine
2.8 Government Regulations
2.8.1 The US Approval and Regulation System
2.8.2 The EU Approval and Regulation System
2.9 Market Definition

3. Next-Generation Cancer Diagnostics: World Market 2015-2025
3.1 The Global Next-Generation Cancer Diagnostics Market: Overview
3.2 The Global Next-Generation Cancer Diagnostics Market Forecast 2015-2025
3.3 How Will Segmental Market Shares Change to 2025?
3.4 Biomarkers and Molecular Diagnostics
3.4.1 Biomarkers and Diagnostic Tests for Breast Cancer
3.4.2 Biomarkers and Diagnostic Tests for Prostate Cancer
3.4.3 Biomarkers and Diagnostic Tests for Colorectal Cancer
3.5 Companion Diagnostics and Collaborations between Two Industries
3.6 LDTs to be Replaced by Approved Tests
3.7 Decentralisation of Diagnostic Tests
3.8 Next-Generation Cancer Diagnostics: Drivers and Restraints 2015-2025

4. Next-Generation Cancer Diagnostics Submarkets 2015-2025
4.1 Advanced PCR Techniques
4.1.1 Advanced PCR Techniques Market Forecast 2015-2025
4.1.2 Leading Products in the Real-Time PCR Market
4.1.2.1 cobas 4800 System and Oncology Tests (Roche)
4.1.2.2 QuantStudio Dx and 7500 Fast Dx (Thermo Fisher)
4.1.2.3 Rotor-Gene Q and therascreen Tests (Qiagen)
4.1.2.4 Oncotype DX (Genomic Health)
4.1.3 Leading Products in the Digital PCR Market
4.1.4 Pap Tests Being Replaced by PCR Assays
4.1.5 Advanced PCR-Based Techniques: Drivers and Restraints 2015-2025
4.2 In Situ Hybridisation (ISH)
4.2.1 ISH Cancer Diagnostics Market Forecast 2015-2025
4.2.2 Leading Products in the ISH Cancer Diagnostics Market
4.2.3 HER2 Tests for Breast Cancer
4.2.4 ISH Cancer Diagnostics: Drivers and Restraints 2015-2025
4.3 Circulating Tumour Cells (CTCs) Analysis
4.3.1 CTCs Analysis Market Forecast 2015-2025
4.3.2 Leading Product in the CTCs Analysis Market
4.3.2.1 CellSearch System (Janssen Diagnostics)
4.3.3 Epic Sciences and LabCorp to Expand in Asia Markets
4.3.4 CTCs Separation by Ultrasound
4.3.5 CTC Clusters More Likely to Cause Metastasis?
4.3.6 CTCs Analysis: Drivers and Restraints 2015-2025
4.4 Microarray
4.4.1 Microarray Cancer Diagnostics Market Forecast 2015-2025
4.4.2 Leading Products in the Microarray Market
4.4.2.1 OncoScan FFPE Assay Kit (Affymetrix)
4.4.2.2 MammaPrint (Agendia)
4.4.3 Microarray Cancer Diagnostics: Trends and Developments
4.4.3.1 Array Comparative Genomic Hybridisation (Array CGH)
4.4.4 Microarray Cancer Diagnostics: Drivers and Restraints 2015-2025
4.5 Next-Generation Sequencing (NGS)
4.5.1 NGS Cancer Diagnostics Market Forecast 2015-2025
4.5.2 Leading Products in the NGS Market
4.5.2.1 MiSeqDx (Illumina)
4.5.2.2 Ion PGM Dx System (Thermo Fisher)
4.5.2.3 GeneRead DNAseq Targeted Panels V2 (Qiagen)
4.5.3 NGS Cancer Diagnostics: Trends and Developments
4.5.3.1 Myriad Shifting from PCR to NGS Panel
4.5.3.2 Competition in the NGS Market
4.5.3.3 Bio-Rad to Commercialise NGS system for Clinical Use
4.5.3.4 Qiagen Launched NGS Bioinformatics Platform
4.5.4 NGS Cancer Diagnostics: Drivers and Restraints 2015-2025

5. Leading National Markets 2015-2025
5.1 World Next-Generation Cancer Diagnostics Market: Regional Forecast 2015-2025
5.1.1 How Will Regional Market Shares Change to 2025?
5.2 US Next-Generation Cancer Diagnostics Market Forecast 2015-2025
5.2.1 FDA Provides Guidance for Molecular Diagnostic Instruments with Combined Functions
5.2.2 Obama Launched 'Precision Medicine Initiative'
5.2.3 FDA and CMS to Regulate LDTs
5.3 EU5 Next-Generation Cancer Diagnostics Market Forecast 2015-2025
5.3.1 Germany: Leading Market in the EU
5.3.2 France: Reduction in Healthcare Spending
5.3.3 UK: 100,000 Genomes Project
5.3.4 Spain: Recovering from Financial Crisis
5.3.5 Italy: Decreasing Reimbursement
5.4 Japanese Next-Generation Cancer Diagnostics Market Forecast 2015-2025
5.4.1 Takeda Collaborated with NCC in Genomic Screening Project
5.4.2 Qiagen Partnered Hitachi on PCR and NGS Technologies
5.4.3 Increase Cancer Rates in Fukushima after Nuclear Disaster?
5.5 Chinese Next-Generation Cancer Diagnostics Market Forecast 2015-2025
5.5.1 Illumina Entering the Chinese Market
5.5.2 Epigenomics Colorectal Cancer Test Approved in China
5.5.3 China Offered Free Screenings for Cervical and Breast Cancer
5.6 Indian Next-Generation Cancer Diagnostics Market Forecast 2015-2025
5.6.1 Lack of Genetic Testing Regulation
5.6.2 Cancer Genetics Launched NGS Cancer Panel in India
5.7 Brazilian Next-Generation Cancer Diagnostics Market Forecast 2015-2025
5.8 Russian Next-Generation Cancer Diagnostics Market Forecast 2015-2025
5.8.1 IBM's Collaboration with Russian Companies to Advance Clinical Decision Making

6. Leading Companies in the Next-Generation Cancer Diagnostics Market 2015
6.1 Roche Diagnostics
6.1.1 Roche Diagnostics: Product Portfolio, 2015
6.1.2 Roche Diagnostics: Diagnostics Outlook
6.1.3 Cobas HPV Test Approved in the US in 2014
6.1.4 Roche Diagnostics: Recent MandA Activity
6.1.5 Roche Coming Back to the NGS Business?
6.2 Abbott Laboratories
6.2.1 Abbott: Next-Generation Cancer Diagnostics Product Portfolio 2015
6.2.2 Abbott: Diagnostics Outlook
6.2.3 Abbott Obtained Exclusive License for Bladder Cancer Biomarker FGFR3
6.3 Qiagen
6.3.1 Qiagen: Next-Generation Cancer Diagnostics Product Portfolio 2015
6.3.1.1 Molecular Diagnostics Kits
6.3.1.2 Real-Time PCR: Rotor-Gene Q
6.3.1.3 Bioinformatics for NGS
6.3.2 Qiagen: Market Outlook
6.3.3 HalioDx Created from Qiagen Marseille
6.4 Thermo Fisher Scientific
6.4.1 Thermo Fisher Scientific: Business Segments
6.4.2 Thermo Fisher: Next-Generation Cancer Diagnostics Product Portfolio 2015
6.4.2.1 QuantStudio 3D (Digital PCR)
6.4.2.2 In Situ Hybridisation
6.4.2.3 Microarray Slides
6.4.2.4 Next-Generation Sequencing
6.4.2.5 Real-Time PCR for Oncology in Pipeline?
6.4.3 Thermo Fisher: Life Sciences Outlook
6.4.4 NGS Oncomine Focus Assay for Oncology Research
6.5 Agilent Technologies
6.5.1 Agilent: Next-Generation Cancer Diagnostics Product Portfolio 2015
6.5.1.1 NGS Enrichment Platforms
6.5.1.2 Cytogenetic Research and Microarrays
6.5.1.3 Other Products
6.5.2 Agilent: Life Sciences and Diagnostics Outlook
6.5.3 Partnerships and Collaborations for Companion Diagnostics
6.6 Hologic
6.6.1 Hologic: Next-Generation Cancer Diagnostics Product Portfolio 2015
6.6.1.1 Aptima HPV Assay and Cervista HPV Assay
6.6.1.2 Progensa PCA3 Assay
6.6.2 Hologic: Diagnostics Sales Outlook
6.7 Illumina
6.7.1 Illumina: Technology and Product Portfolio 2015
6.7.1.1 Sequencing Technology
6.7.1.2 BeadArray Microarray
6.7.1.3 Consumables
6.7.1.4 Services
6.7.2 Illumina: Sales Outlook
6.7.3 Illumina: Recent MandA Activity
6.7.4 Joined Forces with UK Government for 100,000 Genomes Project
6.7.5 Partnered with Merck Serono to Develop NGS Cancer Diagnostics
6.7.6 Investing on Synthetic DNA Manufacturing Technology
6.8 Myriad Genetics
6.8.1 Myriad: Next-Generation Cancer Diagnostics Product Portfolio 2015
6.8.2 Myriad: Sales Outlook
6.8.3 New Landscape in the BRCA Diagnostic Market

7. Qualitative Analysis of the Next-Generation Cancer Diagnostics Market 2015-2025
7.1 SWOT Analysis of the Next-Generation Cancer Diagnostics Market
7.2 Strengths
7.2.1 Global Cancer Rates Set to Soar
7.2.2 Increasing Awareness of Molecular Cancer Diagnostics
7.2.3 The Trend in Precision Medicine
7.3 Weaknesses
7.3.1 Industry Facing Increasing Reimbursement Pressure
7.3.2 Physicians' Reliance on Traditional Methods
7.4 Opportunities
7.4.1 Expanding Biomarkers and Cancer Test Menus
7.4.2 Emerging Market to Provide Future Growth
7.4.3 Companion Diagnostics on the Rise
7.5 Threats
7.5.1 Decreasing Healthcare Spending
7.5.2 Gene Patenting Banned in the US?

8. Research Interviews
8.1 Keith Cannon, Executive Vice President, Aviva Biosciences
8.1.1 Aviva: From Research Laboratories to Clinical and Diagnostic Markets
8.1.2 Ability to Distinguish CTCs is the Key
8.1.3 RedSift(TM): Automated Enrichment of Nucleated Cells
8.1.4 On Drivers and Restraints in the CTC Technologies Market
8.1.5 On the Growth in Regional Markets
8.2 Nobuyoshi Katagiri, Ph.D., Director, Diagnostics Development Department, Oncolys BioPharma
8.2.1 On Future Growth of Oncolys BioPharma
8.2.2 CTCs is Changing the Market
8.2.3 On Current Restraints in the Market
8.2.4 ctDNA May Compete with Oncolys BioPharma's TelomeScan

9. Conclusions
9.1 The World Next-Generation Cancer Diagnostics Market
9.1.1 Current Leading Next-Generation Cancer Diagnostics Segments
9.1.2 Notable Next-Generation Cancer Diagnostics Companies
9.1.3 Leading Regional Markets
9.1.4 World Next-Generation Cancer Diagnostics Market Forecast 2015-2025
9.2 The Future of the Next-Generation Cancer Diagnostics Market

10. Glossary

List of Tables
Table 1.1 Leading National Next-Generation Cancer Diagnostics Market Forecast 2015-2025 ($m, AGR%, CAGR%)
Table 3.1 The Next-Generation Cancer Diagnostics Market: Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 3.2 Selected Biomarkers For Cancer Diagnostics
Table 3.3 FDA Approved Nucleic Acid Based Tests, 2015
Table 3.4 Selected Molecular Diagnostic Tests for Breast Cancer, 2015
Table 3.5 Selected Molecular Diagnostic Tests for Prostate Cancer, 2015
Table 3.6 Selected Molecular Diagnostics Test for Colorectal Cancer, 2015
Table 3.7 Companion Diagnostic Devices Approved by FDA, 2015
Table 4.1 Advanced PCR Techniques Market: Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 4.2 ISH Cancer Diagnostics Market: Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 4.3 CTCs Analysis Market: Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 4.4 Microarray Cancer Diagnostics Market: Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 4.5 NGS Cancer Diagnostics Market: Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 5.1 World Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Region, 2014-2025
Table 5.2 US Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
Table 5.3 EU5 Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
Table 5.4 Japanese Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
Table 5.5 Chinese Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
Table 5.6 Indian Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
Table 5.7 Brazilian Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
Table 5.8 Russian Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
Table 6.1 Roche: Overview, 2015
Table 6.2 Roche Diagnostics: Key Instrument/Device Launches Planned for 2015
Table 6.3 Roche Diagnostics: Key Test Launches Planned for 2015
Table 6.4 Roche Diagnostics: Diagnostics Revenue ($m), AGR (%), CAGR (%), 2010-2014
Table 6.5 Abbott Laboratories: Overview, 2015
Table 6.6 Abbott: Diagnostics Revenue ($m), AGR (%), CAGR (%), 2010-2014
Table 6.7 Qiagen: Overview, 2015
Table 6.8 Qiagen: Molecular Diagnostics Revenue ($m), AGR (%), CAGR (%), 2010-2014
Table 6.9 Thermo Fisher: Overview, 2015
Table 6.10 Thermo Fisher: Life Sciences Solutions Segment Revenue ($m), AGR (%), 2012-2014
Table 6.11 Life Technologies: Revenue ($m), AGR (%), CAGR (%), 2008-2012
Table 6.12 Agilent: Overview, 2015
Table 6.13 Agilent: Life Sciences and Diagnostics Revenue ($m), AGR (%), CAGR (%), 2010-2014
Table 6.14 Hologic: Overview, 2015
Table 6.15 Hologic: Diagnostics Revenue ($m), AGR (%), CAGR (%), 2010-2014
Table 6.16 Illumina: Overview, 2015
Table 6.17 Illumina: Sequencing Product Portfolio 2015
Table 6.18 Illumina: Microarray Product Portfolio 2015
Table 6.19 Illumina: Revenue ($m), AGR (%), CAGR (%), 2010-2014
Table 6.20 Myriad: Overview, 2015
Table 6.21 Myriad: Revenue ($m), AGR (%), CAGR (%), 2010-2014
Table 7.1 SWOT Analysis of the Next-Generation Cancer Diagnostics Market, 2015-2025

List of Figures
Figure 1.1 New Cancer Cases and Deaths in More Developed and Less Developed Regions in 2012
Figure 1.2 Global Next-Generation Cancer Diagnostics Market Segmentation Overview 2015
Figure 3.1 Most Common Causes of Cancer Death, 2012
Figure 3.2 The Next-Generation Cancer Diagnostics Market: Revenue ($m), AGR (%), 2014-2025
Figure 3.3 Market Shares (%) of Leading Next-Generation Cancer Diagnostics Market Segments, 2014
Figure 3.4 Market Shares (%) of Leading Next-Generation Cancer Diagnostics Market Segments, 2019
Figure 3.5 Market Shares (%) of Leading Next-Generation Cancer Diagnostics Market Segments, 2025
Figure 3.6 Next-Generation Cancer Diagnostics: Market Drivers and Restraints 2015-2025
Figure 4.1 Advanced PCR Techniques Market: Revenue ($m), AGR (%), 2014-2025
Figure 4.2 Advanced PCR-Based Techniques: Drivers and Restraints 2015-2025
Figure 4.3 ISH Cancer Diagnostics Market: Revenue ($m), AGR (%), 2014-2025
Figure 4.4 ISH Cancer Diagnostics: Drivers and Restraints 2015-2025
Figure 4.5 CTCs Analysis Market: Revenue ($m), AGR (%), 2014-2025
Figure 4.6 CTCs Analysis: Drivers and Restraints 2015-2025
Figure 4.7 Microarray Cancer Diagnostics Market: Revenue ($m), AGR (%), 2014-2025
Figure 4.8 Microarray Cancer Diagnostics: Drivers and Restraints 2015-2025
Figure 4.9 NGS Cancer Diagnostics Market: Revenue ($m), AGR (%), 2014-2025
Figure 4.10 NGS Cancer Diagnostics: Drivers and Restraints 2015-2025
Figure 5.1 New Cancer Cases and Deaths in More Developed and Less Developed Regions in 2012
Figure 5.2 World Next-Generation Cancer Diagnostics Market: Revenues ($m) by Region, 2014-2025
Figure 5.3 World Next-Generation Cancer Diagnostics Market: Market Shares (%) by Regional Market, 2014
Figure 5.4 World Next-Generation Cancer Diagnostics Market: Market Shares (%) by Regional Market, 2019
Figure 5.5 World Next-Generation Cancer Diagnostics Market: Market Shares (%) by Regional Market, 2025
Figure 5.6 US Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), 2014-2025
Figure 5.7 EU5 Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), 2014-2025
Figure 5.8 Japanese Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), 2014-2025
Figure 5.9 Chinese Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), 2014-2025
Figure 5.10 Indian Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), 2014-2025
Figure 5.11 Brazilian Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), 2014-2025
Figure 5.12 Russian Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), 2014-2025
Figure 6.1 Roche Diagnostics: Revenue Share (%) by Segment, 2014
Figure 6.2 Roche Diagnostics: Diagnostics Revenue ($m), AGR (%), 2010-2014
Figure 6.3 Roche Diagnostics: Growth Rate (%) by Region, 2014
Figure 6.4 Abbott: Diagnostics Revenue ($m), AGR (%), 2010-2014
Figure 6.5 Qiagen: Molecular Diagnostics Revenue ($m), AGR (%), 2010-2014
Figure 6.6 Life Technologies: Revenue ($m), AGR (%), 2008-2012
Figure 6.7 Agilent: Life Sciences and Diagnostics Revenue ($m), AGR (%), 2010-2014
Figure 6.8 Hologic: Diagnostics Revenue ($m), AGR (%), 2010-2014
Figure 6.9 Illumina: Revenue Share (%) by Business Segment, 2014
Figure 6.10 Illumina: Revenue Share (%) by Geographic Area, 2014
Figure 6.11 Illumina: Revenue ($m), AGR (%), 2010-2014
Figure 6.12 Myriad: Revenue ($m), AGR (%), 2010-2014
Figure 6.13 Myriad: Revenue Share by Product (%), 2013
Figure 6.14 Myriad: Revenue Share by Product (%), 2014

Companies Listed
454 Life Sciences
Abbott Laboratories
AbbVie
AbVitro
Advanced Cell Diagnostics
Advanced Liquid Logic
Affymetrix
Agendia
Agilent Technologies
Ambry
Amgen
Annoroad
Applied Biosystems
ARCH Venture Partners
AstraZeneca
Atossa Genetics
AvanSci
Aviva Biosciences
BD
Berry Genomics
BGI
Bina Technologies
Biobase
Biochain
BioFluidica
BioMarin Pharmaceutical
bioMerieux
Bio-Rad
BioServe India
BlueGnome
Bristol-Myers Squibb
Bruker
Cancer Genetics
Cepheid
CLC bio
CompanionDx
Counsyl
Crescendo Bioscience
CytoTrack
Dako
DakoCytomation
Danaher
DiagnoCure
DxS
Eli Lilly
Enzymatics
Epic Sciences
Epicentre Technologies
Epigenomics
Exact Sciences
Fidelity Management
Fluidigm
Fluxion
GeneDx
Genentech
Genia Technologies
Genomic Health
Gen-Probe
GnuBio
HalioDX
Hitachi High-Technologies
Hologic
Idaho Technology
IGEN International
Illumina
Ingenuity Systems
Insilico Medicine
Invitae
Invitrogen
Ipsogen
Iquum
Iris Molecular Diagnostics
Janssen Biotech
Janssen Diagnostics
LabCorp
Life Technologies
Luminex Corporation
Manostring Technologies
Merck
Miltenyi Biotec
Mylan
Myraqa
Myriad Genetics
NextBio
Oncolys BioPharma
Ono Pharmaceutical
Oxford Nanopore
Pacific Biosciences
Pathway Genomics
Pathway Pharmaceuticals
Pensabio
PerkinElmer
Pfizer
Prosigna
Qiagen
Qiagen Marseille
Quest Diagnostics
Quidel
RainDance Technologies
Rarecells
Roche Diagnostics
Sakura
Sanofi
ScreenCell
Siemens
Signature Diagnostics
Silicon Biosystems
SRI Biosciences
Stratos Genomics
Sysmex
Takeda
Thermo Fisher Scientific
Twist Bioscience
Ventana Medical Systems
Verinata Health
Vysis

Other Organisations Mentioned in This Report
Actionable Genome Consortium
Arizona State University
Carnegie Mellon University
First Oncology Research and Advisory Center
Genomics England
Institut Curie
MGH Cancer Center
Massachusetts Institute of Technology
National Cancer Center
Paris-Descartes University
Pennsylvania State University

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Cancer Diagnostics 2020: Supplier Shares and Strategies, Country Segment Forecasts, Technology Trends, Emerging Opportunities--Tumor Markers, Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains

Cancer Diagnostics 2020: Supplier Shares and Strategies, Country Segment Forecasts, Technology Trends, Emerging Opportunities--Tumor Markers, Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains

  • $ 21100
  • Industry report
  • October 2016
  • by Venture Planning Group

Complete report $34,750.  DataPack (test volumes, sales forecasts, supplier shares) $21,100.  The report is available by country, section, market segment, and can be custom-tailored to your specific ...

Cancer Diagnostics Market Segmentation Analysis: Cancer Clinics, Commercial Labs, Hospitals, Physician Offices--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains

Cancer Diagnostics Market Segmentation Analysis: Cancer Clinics, Commercial Labs, Hospitals, Physician Offices--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains

  • $ 21100
  • Industry report
  • August 2016
  • by Venture Planning Group

Complete report $34,500.  DataPack (test volumes, sales forecasts, supplier shares) $21,100.  The report is available by country, section, market segment, and can be custom-tailored to your specific ...

Europe Cancer Diagnostics Market Future Horizons and Growth Strategies: Supplier Shares by Tumor Marker, Country Segment Forecasts, Competitive Intelligence, Opportunities

Europe Cancer Diagnostics Market Future Horizons and Growth Strategies: Supplier Shares by Tumor Marker, Country Segment Forecasts, Competitive Intelligence, Opportunities

  • $ 12800
  • Industry report
  • August 2016
  • by Venture Planning Group

Complete report $19,700.  DataPack (test volumes, sales forecasts, supplier shares) $12,800.VPGMarketResearch.com's new report is a strategic analysis of the major business opportunities emerging in the ...


Download Unlimited Documents from Trusted Public Sources

Global Diagnostics Industry - Forecast

  • May 2016
    23 pages
  • Diagnostics  

    Biomarker  

  • World  

    Europe  

View report >

The future of the Diagnostics Industry in the US and Canada

  • January 2016
    2 pages
  • Diagnostics  

  • United States  

    Canada  

View report >

Global Lung Cancer Statistics - Forecast

  • January 2016
    5 pages
  • Lung Cancer  

    Diagnostics  

  • World  

    North America  

    United States  

View report >

Related Market Segments :

Cancer Diagnostic

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.